CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy-Reference-Cited by-同舟云学术

CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy

Published:2017-09-08 Issue:11 Volume:47 Page:1047-1054
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Isshiki Yusuke¹²,Ohwada Chikako²,Sakaida Emiko²,Onoda Masahiro¹,Aotsuka Nobuyuki³,Tanaka Hiroaki⁴,Fukazawa Motoharu⁵,Cho Ryuko⁶,Sugawara Takeaki⁷,Kawaguchi Takeharu⁸,Hara Satoru⁹,Yokota Akira¹

Affiliation:

1. Department of Hematology, Chiba Aoba Municipal Hospital

2. Department of Hematology, Chiba University Hospital

3. Department of Hematology and Oncology, Japanese Red Cross Narita Hospital

4. Department of Hematology, Asahi General Hospital

5. Department of Internal Medicine, JCHO Funabashi Central Hospital

6. Department of Hematology, Chibaken Saiseikai Narashino Hospital

7. Department of Hematology and Oncology, Chiba Cancer Center

8. Department of Hematology, Oami Municipal Hospital

9. Department of Hematology, Chiba Rosai Hospital, Japan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/47/11/1047/26567515/hyx126.pdf

Reference25 articles.

1. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia;Sebban;J Clin Oncol,1994

2. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial;Thomas;J Clin Oncol,2004

3. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial;Hunault;Blood,2004

4. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993);Goldstone;Blood,2008

5. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison;Cornelissen;Blood,2009

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD20, generalidades básicas-moleculares y su posible relación como marcador de mal pronóstico en leucemia;Revista Colombiana de Cancerología;2023-03-30

2. Pediatric chemotherapy versus allo-HSCT for adolescent and adult Philadelphia chromosome-negative ALL in first complete remission: a meta-analysis;Annals of Hematology;2023-03-22

3. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial;The Lancet Haematology;2022-04

4. Risk Factors for Relapse of Childhood B Cell Acute Lymphoblastic Leukemia;Medical Science Monitor;2020-07-03

5. Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia;Frontiers in Immunology;2019-12-20